Rotator cuff repair is one of the most common procedures in orthopedic surgery. We do it well. The technique is established, the implants are excellent, and rehabilitation protocols are refined. And yet, re-tear rates after surgical repair remain stubbornly high — ranging from 20% in small tears to over 60% in large ones.

That number has bothered surgeons for decades. And it should. Because in most cases, it isn't a failure of technique. It's a failure of biology.

Understanding why rotator cuff repairs fail — and what can be done about it at the cellular level — is one of the most interesting frontiers in shoulder surgery right now. A growing body of research is pointing toward specific biological pathways that govern how tendons heal, and toward compounds that may be able to modulate those pathways in clinically meaningful ways.

This post is for patients and clinicians who want to understand that science. It is not a treatment recommendation, and the compounds discussed are not FDA-approved for this application. But the biology is real, the research is serious, and the conversation is worth having.

Why Rotator Cuff Repairs Fail: The Biology of the Enthesis

The rotator cuff doesn't simply attach tendon to bone. It does something more sophisticated — and more fragile.

The attachment site, called the enthesis, is a gradient structure that transitions from soft, flexible tendon tissue to rigid bone across a distance of just a few millimeters. This transition zone includes fibrocartilage layers with a highly organized collagen architecture. It is what allows the tendon to transfer load to bone without stress concentration that would otherwise cause constant tearing at the interface.

The enthesis is nearly avascular — it has almost no blood supply. This is the single most important biological bottleneck in rotator cuff healing.

‍

Here's the problem: the enthesis is nearly avascular. Blood vessels stop short of the attachment zone. This means that when you repair a torn rotator cuff and reattach tendon to bone, you are asking tissue with virtually no circulatory support to regenerate a complex gradient structure — under load, in a mechanically demanding environment, in a patient who is often older, deconditioned, or has already experienced some degree of fatty infiltration of the surrounding muscle.

The native healing response to this environment is inadequate. The body attempts to bridge the gap with scar tissue — primarily type III collagen — rather than restoring the organized, type I collagen-dominant architecture of the original enthesis. The result is mechanically inferior tissue that is prone to re-tear.

This is the biological problem that no suture anchor or arthroscopic technique, however well executed, fully solves.

The Three Phases of Healing — and Where Things Go Wrong

Rotator cuff repair healing proceeds through three overlapping biological phases, each with distinct cellular activities and vulnerabilities.

‍

Inflammatory Phase

Days 0–7

Vasodilation, macrophage recruitment, and early growth factor signaling. Necessary — it clears damaged tissue and initiates the repair cascade. Also the phase most commonly disrupted by NSAIDs, corticosteroids, and smoking. Patients arriving at surgery with chronic inflammation already present are starting from a compromised position.

‍

Proliferative Phase

Weeks 1–6

Where the real biological work happens. Fibroblasts migrate to the repair site, begin laying down extracellular matrix, and establish the early collagen scaffold. The quality of this phase — how organized the collagen deposition is, how well-vascularized the repair site becomes — largely determines whether the final tissue will have meaningful mechanical strength. Critical limitation: fibroblast migration and collagen synthesis both depend on adequate blood supply. In avascular tissue like the enthesis, this supply is inherently limited.

‍

Remodeling Phase

Weeks 6–12+

Gradual conversion of type III collagen to type I, progressive mechanical organization of collagen fibers along lines of stress, and the slow recovery of tensile strength. This phase can extend for 12 months or more. The systemic hormonal environment — particularly the growth hormone/IGF-1 axis — plays a meaningful role in driving it.

‍

The re-tear problem is concentrated at the intersection of the proliferative and early remodeling phases. If the repair site hasn't established sufficient vascularity and collagen scaffold by week six, the transition to remodeling is compromised from the start.

The Growth Hormone / IGF-1 Axis and Connective Tissue

Growth hormone (GH) and its downstream mediator, insulin-like growth factor 1 (IGF-1), play a well-documented role in connective tissue biology. This isn't fringe science — it's established endocrinology with decades of peer-reviewed literature behind it.

IGF-1 receptors are present on tendon fibroblasts. When activated, IGF-1 drives several processes directly relevant to rotator cuff repair: collagen type I synthesis, tenocyte proliferation, extracellular matrix production, and matrix remodeling enzyme regulation.

14 days of growth hormone supplementation in healthy adults increased collagen synthesis in tendon by up to six-fold — without affecting myofibrillar protein synthesis.

‍

A particularly striking human study published in the Journal of Physiology demonstrated that 14 days of growth hormone supplementation in healthy adults increased collagen synthesis in tendon by up to six-fold — without affecting myofibrillar protein synthesis. This selectivity matters. It suggests GH axis stimulation has a specific and meaningful effect on connective tissue, not simply a global anabolic effect.

The challenge with exogenous growth hormone is that supraphysiologic levels appear to be counterproductive in the repair setting. A randomized clinical trial of recombinant human GH administered after rotator cuff repair showed no significant benefit — and at higher doses, some studies suggest it may actually impair tendon-to-bone mechanical properties. The supra-physiologic GH levels produced by exogenous injection bypass the body's natural pulsatile regulatory mechanisms, and the results reflect that.

This has shifted interest toward growth hormone secretagogues — compounds that stimulate your own pituitary gland to produce growth hormone in a physiologic, pulsatile pattern rather than flooding the system with exogenous hormone. The distinction is biologically significant.

BPC-157: What the Research Actually Shows

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found in gastric juice. It has been studied extensively in animal models of tendon, ligament, muscle, and bone injury — and the results are consistently interesting.

The primary mechanism relevant to rotator cuff repair is angiogenesis. BPC-157 activates the VEGFR2-Akt-eNOS pathway, driving nitric oxide production and the formation of new blood vessels in hypovascular tissues. For the avascular enthesis, this is the mechanism that addresses the single most important biological bottleneck in rotator cuff healing.

In rat models of Achilles tendon transection — the most common preclinical tendon healing model — BPC-157 has consistently produced improvements in biomechanical load-to-failure, histological collagen organization, and functional recovery compared to controls. A 2006 study specifically examining tendon-to-bone healing demonstrated that healing that could not occur spontaneously was recovered with BPC-157 treatment.

BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts — a finding that suggests potential synergy with GH-axis stimulation at the tissue level.

‍

A 2025 systematic review published in the Orthopaedic Journal of Sports Medicine analyzed 36 studies spanning 1993–2024 and concluded that BPC-157 consistently improves functional, structural, and biomechanical outcomes in preclinical musculoskeletal injury models. It also identified an important mechanistic detail: BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts. This means that if growth hormone is elevated — whether through endogenous production or stimulated by a secretagogue — it has more receptors to bind at the tendon level.

The honest limitation: 35 of 36 included studies are preclinical. Human data is extremely limited. BPC-157 is not FDA-approved for any indication, and injectable formulations face regulatory restrictions in the current compounding pharmacy landscape. The gap between compelling animal data and validated human clinical evidence is real and should not be glossed over.

Why the Combination Is Biologically Interesting

The theoretical rationale for combining a local angiogenic agent like BPC-157 with a systemic GH secretagogue is that they target fundamentally different and complementary biological problems.

BPC-157 addresses the local vascular deficit at the enthesis — the bottleneck that limits fibroblast recruitment and early collagen scaffolding during the proliferative phase. Its effects are rapid and localized.

GH secretagogues address the systemic hormonal environment that governs collagen synthesis and matrix maturation across the entire remodeling arc. Their effects are slower to develop — meaningful IGF-1 elevation takes weeks to establish — but they operate across the full healing timeline and have particularly important roles in the remodeling phase when type III collagen is converting to type I.

The BPC-157/GH receptor upregulation finding adds a third layer: local sensitization of the repair tissue to the elevated systemic GH signal. If this finding holds in human tendon tissue, it suggests the compounds may not simply be additive but genuinely synergistic — each making the other more effective.

These are theoretical mechanisms extrapolated from preclinical data. They have not been tested in a human rotator cuff repair trial. That trial does not yet exist. But the mechanistic logic is coherent, the biological targets are real, and the question is legitimate.

What Responsible Use Looks Like

I want to be direct about what "optimization" means in this context — and what it doesn't mean.

It does not mean ordering compounds online and self-administering based on a protocol found on a blog. That approach carries meaningful risk, bypasses the medical oversight that makes any intervention safe, and removes the ability to monitor whether what you're doing is actually working.

Responsible engagement with this science means physician oversight from the beginning. It means baseline laboratory evaluation — including IGF-1 levels and metabolic markers — before initiating any hormonal axis intervention. It means understanding that these compounds interact differently depending on the patient's age, baseline hormonal status, body composition, and the specific nature of their repair.

Compound selection and timing must be matched to individual healing phase biology — not applied as a one-size-fits-all protocol.

‍

It means monitoring labs at appropriate intervals, with compound selection and timing matched to individual healing phase biology rather than applied as a one-size-fits-all protocol. It means understanding the contraindications — active malignancy, significant insulin resistance, certain metabolic conditions — that make some patients poor candidates regardless of their interest in optimization.

And it means full transparency that none of these compounds carry FDA approval for this application. The evidence base is preclinical. The human data is limited. The potential benefits are biologically plausible but not yet proven in the rigorous clinical trial format that establishes standard of care.

Patients who are interested in this approach should have that conversation with their surgeon before their operation — not after. The timing of any intervention matters enormously. Establishing a favorable hormonal baseline weeks before surgery is meaningfully different from starting after the procedure when the early repair window has already passed.

The Research Question That Needs an Answer

The honest truth is that what this field needs is a well-designed randomized controlled trial. Not another animal study — we have plenty of those. A prospective, double-blind, placebo-controlled trial in human patients undergoing rotator cuff repair, with MRI-confirmed structural integrity and validated patient-reported outcomes at six and twelve months.

That trial hasn't been done. The design isn't complicated. The endpoints are established. The mechanistic rationale is more coherent than most interventions that have reached clinical trial stage in orthopedics.

It's the kind of study that could either validate this approach or definitively establish that the preclinical signals don't translate to humans — both outcomes would be scientifically valuable.

Until that trial exists, the conversation sits appropriately in the space between emerging science and established practice. Which is exactly where intellectually honest medicine operates.

About the Author

Patrick Denard, MD is a shoulder surgeon at Oregon Shoulder Institute in Medford, Oregon. He is ranked #2 in North America for rotator cuff repair and #17 globally for shoulder replacement, and has authored over 300 peer-reviewed publications. He performs over 400 shoulder surgeries annually.

Disclosure

This post is for educational purposes only and does not constitute medical advice. The compounds discussed are not FDA-approved for the applications described. Always consult a qualified physician before initiating any medical intervention. Visit oregonshoulder.com for more information.

‍